Furthermore, through animal experiments, the researchers thoroughly verified that two types of AHR antagonists could effectively improve the related symptoms induced by ZIKV infection and identified AHR as a host factor of ZIKV infection and a candidate target for antiviral therapy. The gene discussed is AHR; the disease is Zika virus infectious disease.